DudeDiligence.

FINANCING

Who is raising money: selling new shares, filing room to sell more later, or borrowing. New shares give every holder a smaller slice.

14 filings from 12 companies in the last 7 days, 85 in 30. $17.9B of room filed to sell more. The biggest this week: CLPT, $100M of at-the-market programme.

Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing

Key

Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing

Newest first. A company with several filings is one row; open it for each.

  1. MDAISpectral AI, Inc.Equity line$15.0M45% of value−20.6%8-K ↗
  2. HSCSHeartSciences Inc.At-the-market programme, with Maxim Group$50.0M4.9x value−13.8%424B5 ↗
  3. CLPTClearPoint Neuro, Inc.At-the-market programme$100.0M45% of value−10.4%
  4. PZGParamount Gold Nevada Corp.At-the-market programme, with Cantor Fitzgerald$20.0M26% of value−10.0%424B5 ↗
  5. MEDSDataMEDS AI, Inc.At-the-market programme$10.0M1.3x value+109.3%
  6. NNVCNanoViricides, Inc.At-the-market programme$8.4M29% of value−1.7%424B5 ↗
  7. XGNExagen Inc.At-the-market programme$50.0M54% of value−4.0%
  8. AZRAzora Therapeutics, Inc.At-the-market programme, with Jefferies$20.0M36% of valueS-3 ↗
  9. TTRXTurn Therapeutics Inc.At-the-market programme$50.0M20% of value−5.3%
  10. MPLTMapLight Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M30% of value−18.1%S-3 ↗
  11. TET1 Energy Inc.At-the-market programme, with Roth Capital Partners$100.0M29% of value−42.4%424B5 ↗
  12. OPTXSyntec Optics Holdings, Inc.At-the-market programme, with H.C. Wainwright$50.0M20% of value−11.2%S-3 ↗
  13. NAKANakamoto Inc.At-the-market programme, with TD Securities (USA)$4.99B−31.2%424B5 ↗
  14. CINGCingulate Inc.At-the-market programme$100.0M1.5x value+4.9%
  15. VATEINNOVATE Corp.At-the-market programme$50.0M1.0x value−22.3%424B5 ↗
  16. CENNCenntro Inc.At-the-market programme, with Pacific Century Securities$100.0M−13.7%424B5 ↗
  17. CTGOContango Silver & Gold Inc.At-the-market programme, with Cantor Fitzgerald$75.0M24% of value−20.3%424B5 ↗
  18. INBXInhibrx Biosciences, Inc.At-the-market programme, with Stifel, Nicolaus$150.0M15% of value−17.2%S-3ASR ↗
  19. LINKInterlink Electronics, Inc.At-the-market programme$7.2M22% of value−26.0%
  20. FATEFate Therapeutics, Inc.At-the-market programme$100.0M89% of value−31.4%
  21. AIROAIRO Group Holdings, Inc.At-the-market programme, with Cantor Fitzgerald$50.0M44% of value−36.0%S-3 ↗
  22. SPCEVirgin Galactic Holdings, Inc.At-the-market programme, with Jefferies$250.0M1.6x value−61.0%424B5 ↗
  23. CADLCandel Therapeutics, Inc.At-the-market programme, with Jefferies$50.0M13% of value−39.9%424B5 ↗
  24. MGTXMeiraGTx Holdings plcAt-the-market programme, with BofA Securities$100.0M13% of value−17.6%S-3ASR ↗
  25. PROKProKidney Corp.At-the-market programme, with Jefferies$200.0M48% of value−8.0%424B5 ↗
  26. NHPNational Healthcare Properties, Inc.At-the-market programme$300.0M20% of value−5.9%
  27. KURAKura Oncology, Inc.At-the-market programme, with Leerink Partners$150.0M24% of value−8.7%S-3ASR ↗
  28. FWDIForward Industries, Inc.At-the-market programme$4.00B−37.4%
  29. ATRAAtara Biotherapeutics, Inc.At-the-market programme, with TD Cowen$23.0M36% of value−21.9%S-3 ↗
  30. PACBPacific Biosciences of California, Inc.At-the-market programme$100.0M20% of value−27.2%
  31. OVIDOvid Therapeutics Inc.At-the-market programme, with Cantor Fitzgerald$75.0M18% of value−22.8%S-3 ↗
  32. TSLXSixth Street Specialty Lending, Inc.At-the-market programme$100.0M6.2% of value−5.4%8-K ↗
  33. HYPRHyperfine, Inc.At-the-market programme, with B. Riley Securities$50.0M86% of value−22.7%S-3 ↗
  34. CAPSCapstone Holding Corp.Equity line with Tumim Stone Capital$20.0M−24.2%8-K ↗
  35. USGOU.S. GoldMining Inc.At-the-market programme$3.2M6.0% of value−30.2%424B5 ↗
  36. GNLGlobal Net Lease, Inc.At-the-market programme, with BofA Securities$300.0M22% of value−12.4%424B5 ↗
  37. ZBIOZenas BioPharma, Inc.At-the-market programme, with Jefferies$200.0M12% of value−15.6%424B5 ↗
  38. ATYRaTyr Pharma, Inc.At-the-market programme, with Jefferies$80.0M−39.8%424B5 ↗
  39. FDUSFidus Investment CorporationAt-the-market programme, with Raymond James & Associates$400.0M55% of value−6.6%424B3 ↗
  40. VSTMVerastem, Inc.At-the-market programme, with Cantor Fitzgerald$100.0M13% of value−32.5%S-3ASR ↗